Literature DB >> 34057655

Monte Carlo simulation of the acquisition conditions for 177Lu molecular imaging of hepatic tumors.

Yuya Sekikawa1,2, Keita Funada1, Go Akamatsu3, Kazuhiko Himuro4, Akihiko Takahashi5, Shingo Baba4, Masayuki Sasaki6.   

Abstract

OBJECTIVE: To examine the impact of acquisition time on Lutetium-177 (177Lu) single-photon emission computed tomography (SPECT) images using Monte Carlo simulation.
METHODS: A gamma camera simulation based on the Monte Carlo method was performed to produce SPECT images. The phantom was modeled on a NEMA IEC BODY phantom including six spheres as tumors. After the administration of 7.4 GBq of 177Lu, radioactivity concentrations of the tumor/liver at 6, 24, and 72 h after administration were set to 1.85/0.201, 2.12/0.156, and 1.95/0.117 MBq/mL, respectively. In addition, the radioactivity concentrations of the tumor at 72 h after administration varied by 1/2, 1/4, and 1/8 when comparison was made. Acquisition times examined were 1.2, 1.5, 2, 3, 6, and 12 min. To assess the impact of collimators, SPECT data acquired at 72 h after the administration using six collimators of low-energy high-resolution (LEHR), extended low-energy general-purpose (ELEGP), medium-energy, and general-purpose (MEGP-1, MEGP-2, and MEGP-3) and high-energy general-purpose (HEGP) were examined. After prefiltering using a Butterworth filter, projection images were reconstructed using ordered subset expectation maximization. The detected photons were classified into direct rays, scattered rays, penetrating rays, and characteristic X-rays from lead. The image quality was evaluated through visual assessment, and physical assessment of contrast recovery coefficient (CRC) and contrast-to-noise ratio (CNR). In this study, the CNR threshold for detectability was assumed to be 5.0.
RESULTS: To compare collimators, the highest sensitivity was observed with ELEGP, followed by LEHR and MEGP-1. The highest ratio of direct ray was also observed in ELEGP followed by MEGP-1. In comparison of the radioactivity concentration ratios of tumor/liver, CRC and CNR were significantly decreased with smaller radioactivity concentration ratios. This effect was greater with larger spheres. According to the visual assessment, the acquisition time of 6, 6, and 3 min or longer was required using ELEGP collimator at 6, 24, and 72 h after administration, respectively. Physical assessment based on CNR and CRC also suggested that 6, 6, and 3 min or longer acquisition time was necessary at 6, 24, and 72 h after administration.
CONCLUSION: 177Lu-SPECT images generated via the Monte Carlo simulation suggested that the recommended acquisition time was 6 min or longer at 6 and 24 h and 3 min or longer at 72 h after administration.

Entities:  

Keywords:  177Lu SPECT; Lutetium-177; Monte Carlo simulation; Theranostics

Year:  2021        PMID: 34057655     DOI: 10.1007/s12149-021-01620-9

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  6 in total

1.  Performance of OSEM and depth-dependent resolution recovery algorithms for the evaluation of global left ventricular function in 201Tl gated myocardial perfusion SPECT.

Authors:  Doumit Daou; Isabelle Pointurier; Carlos Coaguila; Didier Vilain; Abdel Wahab Benada; Rachida Lebtahi; Thierry Fourme; Michel Slama; Dominique Le Guludec
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

2.  German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

Authors:  Kambiz Rahbar; Hojjat Ahmadzadehfar; Clemens Kratochwil; Uwe Haberkorn; Michael Schäfers; Markus Essler; Richard P Baum; Harshad R Kulkarni; Matthias Schmidt; Alexander Drzezga; Peter Bartenstein; Andreas Pfestroff; Markus Luster; Ulf Lützen; Marlies Marx; Vikas Prasad; Winfried Brenner; Alexander Heinzel; Felix M Mottaghy; Juri Ruf; Philipp Tobias Meyer; Martin Heuschkel; Maria Eveslage; Martin Bögemann; Wolfgang Peter Fendler; Bernd Joachim Krause
Journal:  J Nucl Med       Date:  2016-10-20       Impact factor: 10.057

3.  Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.

Authors:  Shankar Vallabhajosula; Stanley J Goldsmith; Klaus A Hamacher; Lale Kostakoglu; Shota Konishi; Mathew I Milowski; David M Nanus; Neil H Bander
Journal:  J Nucl Med       Date:  2005-05       Impact factor: 10.057

4.  Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival.

Authors:  S Rudisile; A Gosewisch; V Wenter; M Unterrainer; G Böning; F J Gildehaus; W P Fendler; C J Auernhammer; C Spitzweg; P Bartenstein; A Todica; H Ilhan
Journal:  BMC Cancer       Date:  2019-08-08       Impact factor: 4.430

5.  Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results.

Authors:  Ambreen Khawar; Elisabeth Eppard; Frank Roesch; Hojjat Ahmadzadehfar; Stefan Kürpig; Michael Meisenheimer; Florian C Gaertner; Markus Essler; Ralph A Bundschuh
Journal:  EJNMMI Res       Date:  2019-11-28       Impact factor: 3.138

6.  Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours.

Authors:  Yong-Il Kim; Changhoon Yoo; Seung Jun Oh; Sang Ju Lee; Junho Kang; Hee-Sang Hwang; Seung-Mo Hong; Baek-Yeol Ryoo; Jin-Sook Ryu
Journal:  EJNMMI Res       Date:  2020-06-15       Impact factor: 3.138

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.